Published on
July 17, 2025
- 12:00 GMT
Papyrus Therapeutics Study Strengthens Therapeutic Rationale for OPCML Protein Replacement Therapy in Ovarian Cancer
AI-driven transcriptomic analysis of 189 patient tumors reveals OPCML’s control of tumor-growth pathways and identifies new therapeutic targets WEST CHESTER, PA, UNITED STATES, July 17, 2025 /EINPresswire.com/ -- Papyrus Therapeutics, a privately held …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
